LUMEN
11.11.2020 11:02:06 CET | Business Wire | Press release
Lumen, the world’s first hand-held metabolic tracking device, together with Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), have launched a Connect IQ Lumen App and Garmin Health API integration, allowing users to better understand the impact of fitness and nutrition decisions on their body in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005049/en/
Through the CO2 concentration in a single breath, Lumen measures your metabolic health and provides daily personalised nutrition plans and insights into what your body is burning - fats or carbs. Lumen supports fat burn and improves your metabolic flexibility , which is your body's ability to efficiently switch between using carbs and fats as a fuel source.
Garmin activity trackers and smartwatches help you track and share your activities. Thanks to Lumen data and the Garmin Health API integration, Garmin users can now seamlessly integrate their health and activity data such as heart rate, sleep, steps and calories burned, into the Lumen app and instantly optimise their fitness journey.
“We are thrilled to work with Garmin on this crucial integration. We know how important it is for our users to get valuable insights into their fitness and this will allow them to make more informed decisions about their nutrition and improve their metabolic health,” said Lumen CEO, Daniel Tal.
By combining Garmin and Lumen data, users will be able to monitor their carb fuel consumption through notifications that guide them on when to breathe into Lumen and unlock their day or take a post workout breath. Users can now see how their workout affects their metabolism through recovery macros and a comprehensive Garmin workout summary.
“Lumen is an innovative organisation pushing the boundaries on metabolic health and performance optimisation. Garmin’s Connect IQ platform will enable users to act in real-time to make the right fitness and nutrition decisions at every moment,” said Sean McNamara, Garmin Health Senior Manager Sales and Marketing.
For continual metabolic tracking, Garmin users with compatible devices will also have access to crucial Lumen data such as morning insights, daily and weekly Lumen levels and the Lumen Flex Score which indicates the degree of metabolic flexibility . The goal is to make sure that nutrition and metabolic health remain top of mind.
About Garmin Health
Engineered on the inside for life on the outside, Garmin products have revolutionised the wellness industry. Garmin Health provides enterprise solutions that leverage Garmin wearables and the high-quality sensor data they produce for applications in the corporate wellness, population health, and patient monitoring markets. For more information, visit garmin.com/health, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin , twitter.com/garminnews , instagram.com/garminwellness or youtube.com/garmin .
About Garmin Connect IQ
Connect IQ is the app system for Garmin wearables, bike computers, and outdoor handhelds. Connect IQ allows developers to create on-device solutions for Garmin users. Developers use the Connect IQ SDK to develop apps, and then upload their creations to the Connect IQ store . From there, millions of Garmin users can browse thousands of apps including Starbucks, Spotify, and Amazon Music for download to their Connect IQ compatible device .
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month. Lumen’s vision is to improve the world's metabolic health and quality of life by empowering individuals to make smarter decisions about their nutrition and lifestyle. Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Follow us at twitter.com/LumenMetabolism , facebook.com/Lumen.me/ , instagram.com/lumen.me/ , youtube.com/c/Lumendotme
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005049/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press release
Key Takeaways: Enables enterprises to replace high-cost and recurring SaaS licensing fees with high-performance and cost-efficient NVIDIA-based solutions Offerings are derived from Grid Dynamics’ proven customer solutions and leverage NVIDIA’s technology stack Commercially deployed, with additional customers expressing interest NVIDIA and Grid Dynamics jointly presented these solutions at the National Retail Federation (NRF) conference in January 2026 Learn more in NVIDIA’s published blog Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven suc
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press release
Fourth Quarter and Full Year 2025 Financial Highlights Include:Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior yearAdjusted Calculated Billings, full year 2025, up 4.2% from the prior yearAdjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom